Differentiation of bronchodilator effects of indacaterol and formoterol by FEV1 and inspiratory capacity (IC) in patients with COPD Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Inspiratory capacity (IC) and dyspnea during recovery from symptom-limited exercise in COPD patients treated with tiotropium Source: Eur Respir J 2004; 24: Suppl. 48, 214s Year: 2004
The effect of tiotropium on exacerbations and airflow in patients with COPD Source: Eur Respir J 2006; 27: 547-555 Year: 2006
Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD Source: Eur Respir J 2003; 21: 86-94 Year: 2003
Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation, dyspnea and exercise tolerance in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 33s Year: 2006
The effectiveness of procaterol on functional exercise capacity in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 182s Year: 2005
Evaluation of respiratory muscles‘ function in COPD patients treated with tiotropium Source: Eur Respir J 2005; 26: Suppl. 49, 291s Year: 2005
Effects of inhaled formoterol on dynamic hyperinflation during and after incremental treadmill exercise in patients with advanced COPD Source: Eur Respir J 2006; 28: Suppl. 50, 172s Year: 2006
The effect of BiPAP on maximum exercise capacity in patients with COPD Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011
Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD Source: Eur Respir J 2001; 17: 1132-1137 Year: 2001
Pre-exercise inhalation of short-acting ß-agonists (SABA) safely improves exercise performance in severe COPD patients by reducing lung hyperinflation Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Effect of tiotropium on spontaneous expiratory flow-volume curves during exercise in GOLD 1&2 COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Evaluation of the response of airway obstruction to short-acting inhaled broncodilators with using FIV1 and FEV1 in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005
Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001
Yoga breathing improves ventilatory efficiency in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 185s Year: 2007
Effect of umeclidinium/vilanterol (UMEC/VI) on inspiratory capacity/total lung capacity ratio in hyperinflated COPD patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Metronome-paced hyperventilation, CT measurements and exercise to investigate dynamic hyperinflation contrasting tiotropium versus indacaterol treatment in moderate COPD patients Source: International Congress 2015 – Unravelling the mechanisms of symptoms and exercise limitationas in disease Year: 2015
Flow-volumetric inspiratory exerciser and improving of respiratory functional parameters in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 403s Year: 2004
The efficacy of incentive spirometry in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 256s Year: 2002